Kite: Yescarta Quadruples Median Event-Free Survival Duratio

FOSTER CITY (dpa-AFX) - Kite, a Gilead Company (GILD), said that yescarta CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory

Related Keywords

, Kostenloser Wertpapierhandel , Gilead Company , European Medicines Agency , Drug Administration , Second Line Relapsed , Refractory Largeb Cell , Event Free Survival , Biologics License Application , Priority Review , Prescription Drug User Fee Act , European Medicines , Kite , Descarta , Quadruples , Comedian , Event , Tree , Survival , Uration , Refractory , Barge , Fell , Lymphoma ,